Informa
08:00 - 08:50 50 mins
Registration
08:50 - 09:00 10 mins
Chairman's Opening Remarks
09:00 - 10:00 60 mins
Info
Microbiome Therapeutics Europe
Approaching the Human Body Differently: Microbiome Therapeutic areas and moving the path forward
  • Ricardo Valladares - Vice President, Research & Development, Siolta Therapeutics

The Microbiome is one of the hottest areas of personalized medicine being studied. Experts in pharma, biotech, and investors are checking out how they can be a part of this emerging space - and what discoveries are next.

Clinical development and research in multiple therapeutic areas, including allergies, infant health, and microbiome discovery and application beyond the gut.

Learn what is being done to steer the relevance and future direction of the human microbiome frontier.

10:00 - 10:30 30 mins
Info
Microbiome Therapeutics Europe
Early life Microbiome Development: the Interaction of Fungal Species with Diet and Bacteria
  • Wouter De Jonge - Professor of NeuroGastroenterology, AMC Amsterdam

This session will cover studies on early life microbiome development, especially the part of the microbiome that concern fungi n pre-term children, and correlated fungal and bacterial composition to health risks such as NEC and sepsis. This will cover findings in the implication of pre-term birth, the extensive use of antibiotics in early life, and fungi composition in the early life intestinal compartment, highlighting the mechanistic elements of fungi-epithelial function which is relevant for later risks of immune mediated chronic diseases in adulthood.

This session will also consider project lines on microbiota predictive biomarkers in postoperative ileus and anastomotic leakage, in adult patients.

10:30 - 11:00 30 mins
Microbiome Therapeutics Europe
Morning Coffee and Networking
11:00 - 11:45 45 mins
Info
Microbiome Therapeutics Europe
Single-cell dispensing technology - a new tool for isolation and cultivation
  • Julian Riba - CSO, Cytena

This session will cover technology for label-free cell isolation. B.sight, a benchtop instrument for automated isolation of prokaryotic cells, single-cell dispensing technology, and how it can be used to isolate single bacteria from heterogeneous samples such as faeces or sputum for subsequent clonal cultivation or single-cell sequencing. The technology could be an ideal tool for isolation and cultivation of potentially unknown microbial species.

11:45 - 12:15 30 mins
Info
Microbiome Therapeutics Europe
Paragen: Unique Collection to Modulate Microbiome Composition
  • Philippe Gabant - CSO - Founder, SYNGULON

What research and development techniques are used to identify the makeup of the microbiome? Discover the emerging technologies used in microbiome drug development, successful collection and utilization of microbiome modulation.

12:15 - 13:15 60 mins
Microbiome Therapeutics Europe
Lunch and Networking
13:15 - 13:45 30 mins
Info
Microbiome Therapeutics Europe
Engineering the Microbiome: Targeted Bacterial CRISP-Cas proteins
  • Xavier Duportet - CEO, Eligo Bioscience

This talk will cover the disruptive approach into engineering the microbiome by delivering genetic circuit expressing CRISP-Cas or other proteins into targeted bacterial populations of the microbiome.

13:45 - 14:30 45 mins
Info
Microbiome Therapeutics Europe
How can we talk about health care when we don't understand health and we don't care?
  • Larry Weiss - CEO & Founder, Persona Biome

The emerging science of the microbiome is still in its infancy yet it is the driving force behind a transformative scientific revolution. What lies ahead will have broad implications for us as scientists, our companies and academic institutions, our health, and perhaps for our survival. It is worth reflecting on where we are today, how we got here, what we have learned so far, and the limitations of our methods and of our vision. I will present some of the microbiome data from our recent Amazon studies of minimally impacted Yanomami hunter-gatherers, discuss what we are learning about our biological past that is challenging our deeply held ideas about human health.

14:30 - 15:00 30 mins
Info
Microbiome Therapeutics Europe
Microbiome Reference Standards: A Path from Research to Therapeutics Through Higher Quality of Data
  • Raul Cano - CSO, The BioCollective

This session will identify new bio-markers that may serve as disease indicators and to understand biologically-relevant properties of the human gut microbiome, validated measurements that accurately describe various properties of the microbial community are needed, both quantitatively and qualitatively. The availability and compulsory use of the whole stool gut microbiome reference material as well as other reference materials would enable researchers to advance microbiome science through measurement assurance further and faster. While some efforts are currently moving in this direction directed in this area, no clear consensus on methods and criteria for control reagents exists. This session will discuss the current state of the art and novel products in the pipeline as well as suggested uses and scope of applications.

15:00 - 15:30 30 mins
Microbiome Therapeutics Europe
Coffee and Networking
15:30 - 16:00 30 mins
Info
Microbiome Therapeutics Europe
The status of microbiome-derived therapeutics, R&D, new technologies and applications
  • Michel de Baar - Executive Director, Business Development, Europe, MDS

Clinical development and research are advancing at a rapid pace, but multiple questions need to be answered:

Where do human microbiome therapeutics discoveries stand today and what do they mean?

What is next on the horizon for microbiome beyond the gut?

What technologies are being used in clinical stages of microbiome studies?

16:00 - 17:00 60 mins
Microbiome Therapeutics Europe
Showcase Spotlight
17:00 - 18:00 60 mins
Networking Drinks Reception
18:00 - 18:05 5 mins
End of Conference Day 1

* 活動內容有可能不事先告知作更動及調整。